Case Report
Copyright ©2010 Baishideng.
World J Gastroenterol. Mar 21, 2010; 16(11): 1414-1417
Published online Mar 21, 2010. doi: 10.3748/wjg.v16.i11.1414
Table 1 Clinical characteristics of IFN-α-induced severe thrombocytopenia
Report sourceSex/age (yr)Liver disease/treatmentHCV genotype/serotypeBaseline/Lowest PLTs ( × 103/mL)Duration of IFNαtreatmentBleeding tendencyAntiplatelets antibodies/PAIgGMgk in bone marrowTreatmentOutcome
Shrestha et al[8]M/41HCV/IFNαNR6NRYesNegativeIncreasedNRCR
Dourakis et al[9]M/39HCV/IFNαNR→/148 moYesNRIncreasedSteriods/IvIgCR
Dourakis et al[9]F/64HCV/IFNαNR→/106 moYesPositiveIncreasedSteriods/IvIgCR
Tappero et al[10]F/NRHCV/IFNα2aNR→/112 moNRNRNRSteriodsCR
Jiménez-Sáenz et al[11]M/46HCV/IFNα2bNR→/33 yrYesPositiveIncreasedSteriods/IvIgCR
Pockros et al[12]M/61HCV/IFNα1b→/94 moYesPositiveNRSteriodsCR
Sagir et al[13]M/45HCV/Peg-IFNα2bNR147/910 wkYesNegativeIncreasedSteriodsCR
Sevastianos et al[14]F/38HCV, compensated cirrhosis/Peg-IFN2bGroup 4141/54 wkYesPositiveIncreasedSteriods/IvIgCR
Fujii et al[15]F/24HCV/IFNαNR→/1.14 wkYesPositiveIncreasedSteriods/IvIgCR
Dimitroulopoulos et al[16]F/20HCV/IFNαcon-13a→/1128 wkNoPositiveIncreasedSteriods/IvIgCR
Medeiros et al[17]M/40HCV/IFNα /PegIFNα2aNR→/66 moYesPositiveNo performedSteriods/IvIgCR
Nakajima et al[4]M/47HCV/IFNα2a1b75/188 wkYesPositiveIncreasedIFN DiscontinuedNot CR
Lambotte et al[18]F/73HCV/Peg-IFNα2a1b100/42 moYesPositivePeripheral origin of the pancytopeniaSteriods/IvIg/PTCR
Demirtur et al[19]F/40HCV/Peg-INFNR217/613 wkYesPositiveIncreasedDanazol/IvIgCR
Elefsiniotis et al[20]M/27HCV/Peg-IFNα2bNR150/1048 wk (6 mo after IFN discontinued)YesPositiveIncreasedSteriodsCR
Alves Couto et al[21]M/44HCV/Peg-IFNα2bGroup 3164/216 wkNoNegativeIncreasedSteriodsCR
Our hospitalF/54HCV/Peg-IFNα2a1b100/13 moYesPositiveIncreasedSteriods/IvIg/PTCR